Therapeutic approaches targeting the neurotensin receptors

References

• Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973 Oct 10; 248(19):6854–6861.
   PubMed Web of Science ®Google Scholar
• Kitabgi P, Carraway R, Leeman SE. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem. 1976 Nov 25;251(22):7053–7058.
   PubMed Web of Science ®Google Scholar
• Leeman SE, Carraway RE. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann N Y Acad Sci. 1982;400:1–16. .
   PubMed Web of Science ®Google Scholar
• Uhl GR, Snyder SH. Regional and subcellular distributions of brain neurotensin. Life Sci. 1976 Dec 15;19(12):1827–1832.
   PubMed Web of Science ®Google Scholar
• Carraway R, Leeman SE. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J Biol Chem. 1976 Nov 25;251(22):7045–7052.
   PubMed Web of Science ®Google Scholar
• Carraway RE, Mitra SP, Spaulding G. Posttranslational processing of the neurotensin/neuromedin-N precursor. Ann N Y Acad Sci. 1992;668:1–16.
   PubMed Web of Science ®Google Scholar
• Kitabgi P, De Nadai F, Rovère C, et al. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. Ann N Y Acad Sci. 1992;668:30–42.
   PubMed Web of Science ®Google Scholar
• Boules M, Li Z, Smith K, et al. Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne). 2013 Mar 22;4:36.
   PubMedGoogle Scholar
• Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes. 2011 Feb;18(1):75–82.
   PubMedGoogle Scholar
• St-Gelais F, Jomphe C, Trudeau L-E. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci. 2006 Jul;31(4):229–245.
   PubMed Web of Science ®Google Scholar
• Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Regul Pept. 2000 Sep;93(1–3):125–136.
   PubMedGoogle Scholar
• Mazella J, Béraud-Dufour S, Devader C, et al. Neurotensin and its receptors in the control of glucose homeostasis. Front Endocrinol (Lausanne). 2012 Nov 26;3:143. .
   PubMedGoogle Scholar
• Myers RM, Shearman JW, Kitching MO, et al. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem Biol. 2009 Jul 17;4(7):503–525.
   PubMed Web of Science ®Google Scholar
• Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999 Jul;20(7):302–309.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 1990 Jun;4(6):847–854.
   PubMed Web of Science ®Google Scholar
• Chalon P, Vita N, Kaghad M, et al. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 1996 May 20;386(2–3):91–94.
   PubMed Web of Science ®Google Scholar
• Mazella J, Zsürger N, Navarro V, et al. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem. 1998 Oct 9;273(41):26273–26276.
   PubMed Web of Science ®Google Scholar
• Mazella J. Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? Cell Signal. 2001 Jan;13(1):1–6.
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Madsen P, Jacobsen C, et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001 Jun 22;276(25):22788–22796.
   PubMed Web of Science ®Google Scholar
• Elde R, Schalling M, Ceccatelli S, et al. Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci Lett. 1990 Nov 27;120(1):134–138.
   PubMed Web of Science ®Google Scholar
• Vincent JP. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell Mol Neurobiol. 1995 Oct;15(5):501–512.
   PubMed Web of Science ®Google Scholar
• Dubuc I, Sarret P, Labbé-Jullié C, et al. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci. 1999 Jan 1;19(1):503–510.
   PubMed Web of Science ®Google Scholar
• Smith KE, Boules M, Williams K, et al. NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain. Behav Brain Res. 2012 Jun 15;232(1):93–97.
   PubMed Web of Science ®Google Scholar
• Dobner PR. Multitasking with neurotensin in the central nervous system. Cell Mol Life Sci. 2005 Sep;62(17):1946–1963.
   PubMed Web of Science ®Google Scholar
• Hadden MK, Orwig KS, Kokko KP, et al. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacol. 2005 Dec;49(8):1149–1159.
   PubMed Web of Science ®Google Scholar
• Wu Z, Martinez-Fong D, Trédaniel J, et al. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne). 2012;3:184.
   PubMedGoogle Scholar
• Martin S, Vincent J-P, Mazella J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J Neurosci. 2003 Feb 15;23(4):1198–1205.
   PubMed Web of Science ®Google Scholar
• Kandror KV. The role of sortilin in the “Glut4 Pathway”. Commun Integr Biol. 2018 Jan 2;11(1):e1393592.
   Google Scholar
• Dubuc I, Costentin J, Terranova JP, et al. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br J Pharmacol. 1994 Jun;112(2):352–354. .
   PubMed Web of Science ®Google Scholar
• Gully D, Jeanjean F, Poncelet M, et al. Neuropharmacological profile of non-peptide neurotensin antagonists. Fundam Clin Pharmacol. 1995;9(6):513–521. .
   PubMed Web of Science ®Google Scholar
• Betancur C, Canton M, Burgos A, et al. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur J Pharmacol. 1998 Feb 5;343(1):67–77.
   PubMed Web of Science ®Google Scholar
• Gendron L, Perron A, Payet MD, et al. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. Mol Pharmacol. 2004 Dec;66(6):1421–1430.
   PubMed Web of Science ®Google Scholar
• Thomas JB, Giddings AM, Wiethe RW, et al. Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2. J Med Chem. 2014 Sep 11;57(17):7472–7477.
   PubMed Web of Science ®Google Scholar
• Yamauchi R, Usui H, Yunden J, et al. Characterization of beta-lactotensin, a bioactive peptide derived from bovine beta-lactoglobulin, as a neurotensin agonist. Biosci Biotechnol Biochem. 2003 Apr;67(4):940–943.
   PubMed Web of Science ®Google Scholar
• Rostene W, Azzi M, Boudin H, et al. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Ann N Y Acad Sci. 1997 Apr 24;814:125–141. .
   PubMed Web of Science ®Google Scholar
• White JF, Noinaj N, Shibata Y, et al. Structure of the agonist-bound neurotensin receptor. Nat. 2012 Oct 25;490(7421):508–513.
   Google Scholar
• Huang W, Masureel M, Qu Q, et al. Structure of the neurotensin receptor 1 in complex with β-arrestin 1. Nat. 2020 Jan 16;579(7798):303–308.
   Google Scholar
• Egloff P, Hillenbrand M, Klenk C, et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc Natl Acad Sci USA. 2014 Feb 11;111(6):E655–62.
   PubMed Web of Science ®Google Scholar
• Da Costa G, Bondon A, Delalande O, et al. Elucidation by NMR solution of neurotensin in small unilamellar vesicle environment: molecular surveys for neurotensin receptor recognition. J Biomol Struct Dyn. 2013;31(8):809–817.
   PubMed Web of Science ®Google Scholar
• Quistgaard EM, Madsen P, Grøftehauge MK, et al. Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain. Nat Struct Mol Biol. 2009 Jan 4;16(1):96–98.
   PubMed Web of Science ®Google Scholar
• Quistgaard EM, Grøftehauge MK, Madsen P, et al. Revisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensin. Protein Sci. 2014 Sep;23(9):1291–1300. .
   PubMed Web of Science ®Google Scholar
• Andersen JL, Schrøder TJ, Christensen S, et al. Identification of the first small-molecule ligand of the neuronal receptor sortilin and structure determination of the receptor-ligand complex. Acta Crystallogr Sect D, Biol Crystallogr. 2014 Feb;70(Pt 2):451–460. .
   PubMedGoogle Scholar
• Lambert PD, Gross R, Nemeroff CB, et al. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann N Y Acad Sci. 1995 May 10;757:377–389. .
   PubMed Web of Science ®Google Scholar
• Cusack B, McCormick DJ, Pang YP, et al. Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism. J Biol Chem. 1995 Aug 4;270(31):18359–18366.
   PubMed Web of Science ®Google Scholar
• Kleczkowska P, Lipkowski AW. Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation–a review. Eur J Pharmacol. 2013 Sep 15;716(1–3):54–60.
   PubMed Web of Science ®Google Scholar
• Feng Y-P, Wang J, Dong Y-L, et al. The roles of neurotensin and its analogues in pain. Curr Pharm Des. 2015;21(7):840–848.
   PubMed Web of Science ®Google Scholar
• Studler J-M, Kitabgi P, Tramu G, et al. Extensive Co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides. 1988 Apr;11(3):95–100.
   PubMed Web of Science ®Google Scholar
• Popp E, Schneider A, Vogel P, et al. Time course of the hypothermic response to continuously administered neurotensin. Neuropeptides. 2007 Oct;41(5):349–354.
   PubMed Web of Science ®Google Scholar
• Tyler BM, Douglas CL, Fauq A, et al. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacol. 1999 Jul;38(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Boules M, Fredrickson P, Richelson E. Bioactive analogs of neurotensin: focus on CNS effects. Peptides. 2006 Oct;27(10):2523–2533.
   PubMed Web of Science ®Google Scholar
• Lugrin D, Vecchini F, Doulut S, et al. Reduced peptide bond pseaadopeptide analogues of neurotensins binding and biological activities, and in vitro metabolic stability. Eur J Pharmacol. 1991 Nov;205(2):191–198.
   PubMed Web of Science ®Google Scholar
• Boules M, Fredrickson P, Richelson E. Current topics: brain penetrating neurotensin analog. Life Sci. 2003 Oct;73(22):2785–2792.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Matulonis JE, Richelson E, et al. Systemically and topically active antinociceptive neurotensin compounds. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1075–1079.
   PubMed Web of Science ®Google Scholar
• Fanelli R, Besserer-Offroy É, René A, et al. Synthesis and characterization in vitro and in vivo of (l)-(Trimethylsilyl)alanine containing neurotensin analogues. J Med Chem. 2015 Oct 8;58(19):7785–7795.
   PubMed Web of Science ®Google Scholar
• Sousbie M, Besserer-Offroy É, Brouillette RL, et al. In search of the optimal macrocyclization site for neurotensin. ACS Med Chem Lett. 2018 Mar 8;9(3):227–232.
   PubMed Web of Science ®Google Scholar
• Sousbie M, Vivancos M, Brouillette RL, et al. Structural optimization and characterization of potent analgesic macrocyclic analogues of neurotensin (8-13). J Med Chem. 2018 Aug 23;61(16):7103–7115.
   PubMed Web of Science ®Google Scholar
• Doulut S, Rodriguez M, Lugrin D, et al. Reduced peptide bond pseudopeptide analogues of neurotensin. Pept Res. 1992 Feb;5(1):30–38.
   PubMedGoogle Scholar
• Sarret P, Esdaile MJ, Perron A, et al. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J Neurosci. 2005 Sep 7;25(36):8188–8196.
   PubMed Web of Science ®Google Scholar
• Roussy G, Dansereau M-A, Baudisson S, et al. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity. Mol Pain. 2009 Jul 6;5:38.
   PubMed Web of Science ®Google Scholar
• Boules M, Liang Y, Briody S, et al. NT79: A novel neurotensin analog with selective behavioral effects. Brain Res. 2010 Jan 13;1308:35–46. .
   PubMed Web of Science ®Google Scholar
• Einsiedel J, Held C, Hervet M, et al. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics. J Med Chem. 2011 Apr 28;54(8):2915–2923.
   PubMed Web of Science ®Google Scholar
• Held C, Plomer M, Hübner H, et al. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand. ChemMedChem. 2013 Jan;8(1):75–81.
   PubMed Web of Science ®Google Scholar
• Simeth NA, Bause M, Dobmeier M, et al. NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids. Bioorg Med Chem. 2017 Jan 1;25(1):350–359.
   PubMed Web of Science ®Google Scholar
• Eiselt E, Gonzalez S, Martin C, et al. Neurotensin analogues containing cyclic surrogates of tyrosine at position 11 improve NTS2 selectivity leading to analgesia without hypotension and hypothermia. ACS Chem Neurosci. 2019 Nov 20;10(11):4535–4544.
   PubMed Web of Science ®Google Scholar
• Fanelli R, Floquet N, Besserer-Offroy É, et al. Use of molecular modeling to design selective NTS2 neurotensin analogues. J Med Chem. 2017 Apr 27;60(8):3303–3313.
   PubMed Web of Science ®Google Scholar
• Tétreault P, Beaudet N, Perron A, et al. Spinal NTS2 receptor activation reverses signs of neuropathic pain. Faseb J. 2013 Sep;27(9):3741–3752. .
   PubMed Web of Science ®Google Scholar
• Kleczkowska P, Kosson P, Ballet S, et al. PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. Mol Pain. 2010 Dec 6;6:86. .
   PubMed Web of Science ®Google Scholar
• Kleczkowska P, Hermans E, Kosson P, et al. Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile(9)]PK20 in an acute pain treatment in rodents. Brain Res. 2016 Oct 1;1648(Pt A):172–180.
   PubMedGoogle Scholar
• Kern SE, Allen J, Wagstaff J, et al. The pharmacokinetics of the conopeptide contulakin-G (CGX-1160) after intrathecal administration: an analysis of data from studies in beagles. Anesth Analg. 2007 Jun;104(6):1514–1520. . table of contents.
   PubMed Web of Science ®Google Scholar
• Lee H-K, Zhang L, Smith MD, et al. A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties. Front Pharmacol. 2015 Feb 10;6:11. .
   PubMed Web of Science ®Google Scholar
• Ho IHT, Liu X, Zou Y, et al. A novel peptide interfering with proBDNF-sortilin interaction alleviates chronic inflammatory pain. Theranostics. 2019 Feb 28;9(6):1651–1665.
   PubMed Web of Science ®Google Scholar
• Ferraro L, Tiozzo Fasiolo L, Beggiato S, et al. Neurotensin: A role in substance use disorder? J Psychopharmacol (Oxford). 2016 Feb;30(2):112–127. .
   PubMed Web of Science ®Google Scholar
• Torruella-Suárez ML, McElligott ZA. Neurotensin in reward processes. Neuropharmacology. 2020 May 1;167:108005. .
   PubMed Web of Science ®Google Scholar
• Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov. 2012 May 18;11(6):462–478.
   PubMed Web of Science ®Google Scholar
• Boules MM, Fredrickson P, Muehlmann AM, et al. Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. Behav Sci (Basel). 2014 Jun 13;4(2):125–153.
   PubMedGoogle Scholar
• Vadnie CA, Ayers-Ringler J, Oliveros A, et al. Antipsychotic-like effects of a neurotensin receptor type 1 agonist. Behav Brain Res. 2016 May 15;305:8–17. .
   PubMed Web of Science ®Google Scholar
• Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007 Aug;9(4):329–336.
   PubMedGoogle Scholar
• Widerlöv E, Lindström LH, Besev G, et al. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry. 1982 Sep;139(9):1122–1126.
   PubMed Web of Science ®Google Scholar
• Manberg PJ, Nemeroff CB, Bissette G, et al. Neuropeptides in CSF and post-mortem brain tissue of normal controls, schizophrenics and Huntington’s choreics. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(1):97–108. .
   PubMed Web of Science ®Google Scholar
• Feifel D, Minor KL, Dulawa S, et al. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997 Jun 20;760(1–2):80–84.
   PubMed Web of Science ®Google Scholar
• Feifel D, Reza TL, Wustrow DJ, et al. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther. 1999 Feb;288(2):710–713.
   PubMed Web of Science ®Google Scholar
• Cusack B, Boules M, Tyler BM, et al. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 2000 Feb 21;856(1–2):48–54.
   PubMed Web of Science ®Google Scholar
• Boules M, Fredrickson P, Richelson E. Neurotensin agonists as an alternative to antipsychotics. Expert Opin Investig Drugs. 2005 Apr;14(4):359–369. .
   PubMed Web of Science ®Google Scholar
• Sadoul JL, Chécler F, Kitabgi P, et al. Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. Biochem Biophys Res Commun. 1984 Nov 30;125(1):395–404.
   PubMed Web of Science ®Google Scholar
• Uhl GR, Whitehouse PJ, Price DL, et al. Parkinson’s disease: depletion of substantia nigra neurotensin receptors. Brain Res. 1984 Aug 6;308(1):186–190.
   PubMed Web of Science ®Google Scholar
• Boules M, Warrington L, Fauq A, et al. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur J Pharmacol. 2001 Oct 5;428(2):227–233.
   PubMed Web of Science ®Google Scholar
• Díaz-Cabiale Z, Fuxe K, Narváez JA, et al. Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist. Neuroreport. 2002 May 7;13(6):763–766.
   PubMed Web of Science ®Google Scholar
• Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004 Jun;27(3):108–110. .
   PubMed Web of Science ®Google Scholar
• Boules M, Warrington L, Fauq A, et al. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur J Pharmacol. 2001 Aug 24;426(1–2):73–76.
   PubMed Web of Science ®Google Scholar
• Liang Y, Boules M, Shaw AM, et al. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res. 2008 Sep 22;1231:6–15. .
   PubMed Web of Science ®Google Scholar
• Boules M, Oliveros A, Liang Y, et al. A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats. Neuropeptides. 2011 Feb;45(1):9–16. .
   PubMed Web of Science ®Google Scholar
• Betancur C, Cabrera R, de Kloet ER, et al. Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacolog. 1998 Oct;19(4):322–332.
   PubMed Web of Science ®Google Scholar
• Felszeghy K, Espinosa JM, Scarna H, et al. Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference. Neuropsychopharmacolog. 2007 Dec;32(12):2601–2610.
   PubMed Web of Science ®Google Scholar
• Ehlers CL, Somes C, Li TK, et al. Neurotensin studies in alcohol naive, preferring and non-preferring rats. Neuroscience. 1999;93(1):227–236. .
   PubMed Web of Science ®Google Scholar
• Lee MR, Hinton DJ, Song JY, et al. Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice. Pharmacol Biochem Behav. 2010 Apr;95(2):235–241. .
   PubMed Web of Science ®Google Scholar
• Lee MR, Hinton DJ, Unal SS, et al. Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2. Alcohol Clin Exp Res. 2011 Jan;35(1):99–107.
   PubMed Web of Science ®Google Scholar
• Angelidou A, Francis K, Vasiadi M, et al. Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation. 2010 Aug 23;7:48. .
   PubMed Web of Science ®Google Scholar
• Patel AB, Tsilioni I, Leeman SE, et al. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci USA. 2016 Nov 8;113(45):E7049–58.
   PubMed Web of Science ®Google Scholar
• Schroeder LE, Leinninger GM. Role of central neurotensin in regulating feeding: implications for the development and treatment of body weight disorders. Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):900–916.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stoeckli R, Ernst A, et al. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab. 2006 Sep;91(9):3544–3547. .
   PubMed Web of Science ®Google Scholar
• Gevaert B, Wynendaele E, Stalmans S, et al. Blood-brain barrier transport kinetics of the neuromedin peptides NMU, NMN, NMB and NT. Neuropharmacol. 2016 Apr 1;107:460–470.
   PubMed Web of Science ®Google Scholar
• Levine AS, Kneip J, Grace M, et al. Effect of centrally administered neurotensin on multiple feeding paradigms. Pharmacol Biochem Behav. 1983 Jan;18(1):19–23. .
   PubMed Web of Science ®Google Scholar
• Stanley BG, Hoebel BG, Leibowitz SF. Neurotensin: effects of hypothalamic and intravenous injections on eating and drinking in rats. Peptides. 1983 Aug;4(4):493–500.
   PubMed Web of Science ®Google Scholar
• Opland D, Sutton A, Woodworth H, et al. Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity. Mol Metab. 2013 Aug 7;2(4):423–434.
   PubMed Web of Science ®Google Scholar
• Boules M, Cusack B, Zhao L, et al. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 2000 May 19;865(1):35–44.
   PubMed Web of Science ®Google Scholar
• Feifel D, Goldenberg J, Melendez G, et al. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacol. 2010 Jan;58(1):195–198.
   PubMed Web of Science ®Google Scholar
• Brown JA, Bugescu R, Mayer TA, et al. Loss of action via neurotensin-leptin receptor neurons disrupts leptin and ghrelin-mediated control of energy balance. Endocrinol. 2017 May 1;158(5):1271–1288.
   PubMed Web of Science ®Google Scholar
• Ratner C, He Z, Grunddal KV, et al. Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. Diabetes. 2019 Apr 1;68(6):1329–1340.
   PubMed Web of Science ®Google Scholar
• Li J, Song J, Zaytseva YY, et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016 May 19;533(7603):411–415.
   PubMed Web of Science ®Google Scholar
• Rabinowich L, Fishman S, Hubel E, et al. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J Hepatol. 2015 Jan;62(1):175–181.
   PubMed Web of Science ®Google Scholar
• Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012 Oct 10;308(14):1469–1475.
   PubMed Web of Science ®Google Scholar
• Butler MG, Nelson TA, Driscoll DJ, et al. High plasma neurotensin levels in children with Prader-Willi syndrome. Am J Med Genet A. 2015 Aug;167A(8):1773–1778.
   PubMedGoogle Scholar
• Barchetta I, Cimini FA, Capoccia D, et al. Neurotensin is a lipid-induced gastrointestinal peptide associated with visceral adipose tissue inflammation in obesity. Nutrients. 2018 Apr 23;10(4). DOI:10.3390/nu10040526.
   PubMed Web of Science ®Google Scholar
• Osadchii OE. Emerging role of neurotensin in regulation of the cardiovascular system. Eur J Pharmacol. 2015 Sep 5;762:184–192. .
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Lyass A, Liu Y, et al. Circulating proneurotensin concentrations and cardiovascular disease events in the community: the framingham heart study. Arterioscler Thromb Vasc Biol. 2016 Jun 16;36(8):1692–1697.
   PubMed Web of Science ®Google Scholar
• Hubel E, Saroha A, Park W-J, et al. Sortilin deficiency reduces ductular reaction, hepatocyte apoptosis, and liver fibrosis in cholestatic-induced liver injury. Am J Pathol. 2017 Jan;187(1):122–133. .
   PubMed Web of Science ®Google Scholar
• Chen C, Li J, Matye DJ, et al. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J Lipid Res. 2019 Jan 22;60(3):539–549.
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Zhou J, Yang W, et al. Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin Exp Pharmacol Physiol. 2017 Aug;44(8):841–846.
   PubMed Web of Science ®Google Scholar
• Maschauer S, Prante O. Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors. J Labelled Comp Radiopharm. 2018 Jan 5;61(3):309–325.
   PubMed Web of Science ®Google Scholar
• Qiu S, Pellino G, Fiorentino F, et al. A review of the role of neurotensin and its receptors in colorectal cancer. Gastroenterol Res Pract. 2017 Feb 20;2017:6456257. .
   PubMed Web of Science ®Google Scholar
• Nikolaou S, Qiu S, Fiorentino F, et al. The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review. Cell Commun Sig. 2020 Apr 26;18(1):68.
   PubMed Web of Science ®Google Scholar
• Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011 Sep;93(9):1369–1378.
   PubMed Web of Science ®Google Scholar
• Alshoukr F, Rosant C, Maes V, et al. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. Bioconjug Chem. 2009 Aug 19;20(8):1602–1610.
   PubMed Web of Science ®Google Scholar
• Yin X, Wang M, Wang H, et al. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids. 2017 May 23;49(8):1325–1335.
   PubMed Web of Science ®Google Scholar
• Chavatte K, Terriere D, Jeannin L, et al. Labelling and evaluation of new stabilised neurotensin (8-13) analogues for single photon emission tomography (SPET). J Label Compd Radiopharm. 1999 May;42(5):423–435. .
   Web of Science ®Google Scholar
• Chavatte K, Wong E, Fauconnier TK, et al. Rhenium (Re) and technetium (Tc)-99M oxocomplexes of neurotensin(8-13). J Label Compd Radiopharm. 1999 May;42(5):415–421. .
   Web of Science ®Google Scholar
• García-Garayoa E, Allemann-Tannahill L, Bläuenstein P, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8–13) analogues with high affinity for NT1 receptors. Nucl Med Biol. 2001 Jan;28(1):75–84. .
   PubMed Web of Science ®Google Scholar
• Prignon A, Provost C, Alshoukr F, et al. Preclinical evaluation of 68Ga-DOTA-NT-20.3: a promising PET imaging probe to discriminate human pancreatic ductal adenocarcinoma from pancreatitis. Mol Pharm. 2019 Jun 3;16(6):2776–2784.
   PubMedGoogle Scholar
• Buchegger F, Bonvin F, Kosinski M, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003 Oct;44(10):1649–1654.
   PubMed Web of Science ®Google Scholar
• Maina T, Nikolopoulou A, Stathopoulou E, et al. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imag. 2007 Nov;34(11):1804–1814.
   PubMed Web of Science ®Google Scholar
• Gabriel M, Decristoforo C, Wöll E, et al. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Cancer Biother Radiopharm. 2011 Oct;26(5):557–563. .
   PubMed Web of Science ®Google Scholar
• García-Garayoa E, Bläuenstein P, Blanc A, et al. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imag. 2009 Jan;36(1):37–47.
   PubMed Web of Science ®Google Scholar
• Hillairet De Boisferon M, Raguin O, Thiercelin C, et al. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug Chem. 2002 Jun;13(3):654–662. .
   PubMed Web of Science ®Google Scholar
• Alshoukr F, Prignon A, Brans L, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011 Jul 20;22(7):1374–1385.
   PubMed Web of Science ®Google Scholar
• Maschauer S, Ruckdeschel T, Tripal P, et al. In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study. Pharmaceuticals (Basel). 2014 Apr 16;7(4):464–481.
   PubMedGoogle Scholar
• Mascarin A, Valverde IE, Vomstein S, et al. 1,2,3-triazole stabilized neurotensin-based radiopeptidomimetics for improved tumor targeting. Bioconjug Chem. 2015 Oct 21;26(10):2143–2152.
   PubMed Web of Science ®Google Scholar
• Deng H, Wang H, Zhang H, et al. Imaging neurotensin receptor in prostate cancer with 64Cu-labeled neurotensin analogs. Mol Imaging. 2017 Dec;16:1536012117711369.
   Web of Science ®Google Scholar
• Maschauer S, Greff C, Einsiedel J, et al. Improved radiosynthesis and preliminary in vivo evaluation of a (18)F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2. Bioorg Med Chem. 2015 Jul 15;23(14):4026–4033.
   PubMed Web of Science ®Google Scholar
• Lang C, Maschauer S, Hübner H, et al. Synthesis and evaluation of a (18)F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors. J Med Chem. 2013 Nov 27;56(22):9361–9365.
   PubMed Web of Science ®Google Scholar
• Mun J, Yang L, Goodman M, et al. MicroPET and bio-distribution of [11C]SR48692, a selective antagonist for neurotensin receptor 1, in a nude mouse model bearing two subcutaneous human pancreatic adenocarcinoma xenografts, MIA PaCa-2. J Nucl Med. 2019 May 1;60(supplement 1):1396.
   Google Scholar
• Schulz J, Rohracker M, Stiebler M, et al. Comparative evaluation of the biodistribution profiles of a series of nonpeptidic neurotensin receptor-1 antagonists reveals a promising candidate for theranostic applications. J Nucl Med. 2016 Jul;57(7):1120–1123. .
   PubMed Web of Science ®Google Scholar
• Schulz J, Rohracker M, Stiebler M, et al. Proof of therapeutic efficacy of a 177Lu-labeled neurotensin receptor 1 antagonist in a colon carcinoma xenograft model. J Nucl Med. 2017 Mar 2;58(6):936–941.
   PubMed Web of Science ®Google Scholar
• Baum RP, Singh A, Schuchardt C, et al. 177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med. 2018;59(5):809–814. .
   PubMed Web of Science ®Google Scholar
• Deng H, Wang H, Wang M, et al. Synthesis and evaluation of 64Cu-DOTA-NT-Cy5.5 as a dual-modality PET/fluorescence probe to image neurotensin receptor-positive tumor. Mol Pharm. 2015 Aug 3;12(8):3054–3061.
   PubMedGoogle Scholar
• Renard E, Dancer P-A, Portal C, et al. Design of bimodal ligands of neurotensin receptor 1 for positron emission tomography imaging and fluorescence-guided surgery of pancreatic cancer. J Med Chem. 2020 Mar 12;63(5):2426–2433.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang H, Wang H, et al. Development of [18F]AlF-NOTA-NT as PET agents of neurotensin receptor-1 positive pancreatic cancer. Mol Pharm. 2018 Aug 6;15(8):3093–3100.
   PubMedGoogle Scholar
• Falciani C, Brunetti J, Lelli B, et al. Cancer selectivity of tetrabranched neurotensin peptides is generated by simultaneous binding to sulfated glycosaminoglycans and protein receptors. J Med Chem. 2013 Jun 27;56(12):5009–5018.
   PubMed Web of Science ®Google Scholar
• Thomas JB, Runyon SP Compounds active at the neurotensin receptor. WO2011156557A2. 2011 Dec 15;1–33.
   Google Scholar
• Fan Y, Lai MH, Sullivan K, et al. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5789–5791.
   PubMed Web of Science ®Google Scholar
• Thomas JB, Giddings AM, Olepu S, et al. Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2. Bioorg Med Chem Lett. 2015 Jan 15;25(2):292–296.
   PubMed Web of Science ®Google Scholar
• Di Fruscia P, He Y, Koenig M, et al. The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1). Bioorg Med Chem Lett. 2014 Aug 15;24(16):3974–3978.
   PubMed Web of Science ®Google Scholar
• Research Triangle Institute. Pyrazole compounds selective for Neurotensin 2 receptor. WO2015148465A1. 2015 Oct 1;1–78.
   Google Scholar
• Thomas JB, Giddings AM, Wiethe RW, et al. Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound. J Med Chem. 2014 Jun 26;57(12):5318–5332.
   PubMed Web of Science ®Google Scholar
• Sanford-Burnham Research Institute. Small molecule agonists of neurotensin receptor 1. WO2014100501A1. 2014 Jun 26;1–200.
   Google Scholar
• Peddibhotla S, Hedrick MP, Hershberger P, et al. Discovery of ML314, a brain penetrant non-peptidic β-arrestin biased agonist of the neurotensin NTR1 receptor. ACS Med Chem Lett. 2013 Jul 20;4(9):846–851.
   PubMed Web of Science ®Google Scholar
• Barak LS, Bai Y, Peterson S, et al. ML314: A biased neurotensin receptor ligand for methamphetamine abuse. ACS Chem Biol. 2016 Jul 15;11(7):1880–1890.
   PubMed Web of Science ®Google Scholar
• Hershberger PM, Hedrick MP, Peddibhotla S, et al. Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg Med Chem Lett. 2014 Jan 1;24(1):262–267.
   PubMed Web of Science ®Google Scholar
• Sanford-Burnham Research Institute. Small molecule agonists of neurotensin receptor 1. WO2015200534A2. 2015 Dec 30;1–306.
   Google Scholar
• Pinkerton AB, Peddibhotla S, Yamamoto F, et al. Discovery of β-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators. J Med Chem. 2019 Sep 12;62(17):8357–8363.
   PubMed Web of Science ®Google Scholar
• Slosky LM, Bai Y, Toth K, et al. β-arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors. Cell. 2020 Jun 11;181(6):1364–1379.e14. .
   PubMed Web of Science ®Google Scholar
• Institut National de la Sante et de la Recherche (INSERM). Neurotensin receptor analogues for radioisotope targeting to neurotensin receptor-positive tumors. US20120207676A1. 2012 Aug 16;1–19.
   Google Scholar
• Institut National De La Sante De La Recherche (INSERM). Methods and Pharmaceutical compositions (NTSR1) inhibitors for the treatment of hepatocellular carcinomas. WO2016189091Al. 2016 Dec 1;1–44.
   Google Scholar
• University of Kentucky Research Foundation. Method of predicting obesity. US20170248610A1. 2017 Aug 31;1–44.
   Google Scholar
• Maschauer S, Einsiedel J, Hübner H, et al. 18)F- and (68)Ga-labeled neurotensin peptides for PET imaging of neurotensin receptor 1. J Med Chem. 2016 Jul 14;59(13):6480–6492.
   PubMed Web of Science ®Google Scholar
• Friedrich-Alexander-Universitat. Diagnosis, treatment and prevention of neurotensin-related conditions. WO2018024789A1. 2018 Feb 8;1–55.
   Google Scholar
• University of Southern California USC Stevens. Vinyl sulfone-based 18-F labeling compositions and methods and uses thereof. WO2014138720A1. 2014 Sep 12;1–68.
   Google Scholar
• Vect-Horus and Centre National De La Recherche Scientifique. Activated neurotensin molecules and the uses thereof. US20160354480A1. 2016 Dec 8;1–42.
   Google Scholar
• Centre National De Le Recherche Scientifique (CNRS). Diagnosis and monitoring treatment of psychiatric diseases with spandin and related methods. US20120322060A. 2012 Dec 20;1–35.
   Google Scholar
• Centre National De La Recherche Scientifique and Universtite De Nice. Peptides derived from the Propeptide NTSR3 and their use in the treatment of depression. US20190270771A1. 2019 Sep 5;1–14.
   Google Scholar
• The Brigham and Young Womens Hospital. Sortilin 1 is a novel inducer of vascular calcification. WO2014071131A1. 2014 May 8;1–97.
   Google Scholar
• Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof. WO 2010063122 Al. 2010 Jun 10;1–79.
   Google Scholar
• Angichem Inc. Multimeric peptides conjugates and uses thereof. WO2011000095A1. 2011 Jan 6;1–133.
   Google Scholar
• Ghatnekar GS, Brower J Methods and compositions for treatment of metabolic disorders. US 20120238490A1. 2012 Sep 20;1–44.
   Google Scholar
• Halimed Pharmaceuticals Inc. Methods and compositions for the treatment of metabolic disorders. US8476,221B2. 2013 Jul 2;1–33.
   Google Scholar
• Li H, Hua T, Wang W, et al. The effects of pharmacological hypothermia induced by neurotensin receptor agonist ABS 201 on outcomes of CPR. Shock. 2019;51(5):667–673.
   PubMed Web of Science ®Google Scholar
• Lee JH, Wei L, Gu X, et al. Therapeutic effects of pharmacologically induced hypothermia against traumatic brain injury in mice. J Neurotrauma. 2014 Aug 15;31(16):1417–1430.
   PubMed Web of Science ®Google Scholar
• Tarveda Therapeutics Inc. Neurotensin receptor binding conjugates anf formulations thereof. WO2017180834A1. 2017 Oct 19;1–178.
   Google Scholar
• 3B Pharmaceuticals GMBH. Neurotensin receptor ligands. WO2014086499A1. 2014 Jun 12;1–159.
   Google Scholar
• 3B Pharmaceuticals GMBH. Conjugate comprising a neurotensin receptor ligand and use therof. WO2015188934A1. 2015 Dec 17;1–305.
   Google Scholar
• LundbeckAS H. Design of specific ligands to sortilin. US20110160439A1. 2011 Jun 30;1–304.
   Google Scholar
• Lundbeck H AS. N-substituted 5-substituted thalamic acids as sortilin inhibitors. WO2014114779A1. 2014 Jul 31;1–107.
   Google Scholar
• Lundbeck H AS. Modulation of the VPS10P-domain receptor family for the treatment of the mental and behavioural disorders. US2017024061A1. 2017 Aug 24;1–104.
   Google Scholar
• Faming Sheqing. 8-Hydroxyquinolines NTR1 micromolecular antagonist and its application. CN104744439A. 2015 Jan 7;1–11.
   Google Scholar
• Faming Sheqing. One class of NTR1 small molecular antagonist. CN104744455A. 2015 Jan 7;1–11.
   Google Scholar
• Stachel SJ, Ginnetti AT, Johnson SA, et al. Identification of potent inhibitors of the sortilin-progranulin interaction. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127403.
   PubMed Web of Science ®Google Scholar